NextCure, Inc. (NASDAQ:NXTC – Free Report) – Equities researchers at HC Wainwright issued their FY2030 earnings per share estimates for shares of NextCure in a note issued to investors on Wednesday, July 15th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.18) per share for the year. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for NextCure’s current full-year earnings is ($7.90) per share.
Other analysts have also recently issued reports about the stock. Weiss Ratings cut shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.00.
NextCure Stock Performance
Shares of NXTC stock opened at $6.63 on Thursday. NextCure has a fifty-two week low of $1.55 and a fifty-two week high of $15.74. The firm has a market capitalization of $23.95 million, a price-to-earnings ratio of -0.39 and a beta of 1.42. The stock’s 50-day simple moving average is $4.59 and its 200-day simple moving average is $9.37.
NextCure (NASDAQ:NXTC – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23.
Institutional Investors Weigh In On NextCure
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new position in shares of NextCure during the 4th quarter worth approximately $160,000. Millennium Management LLC purchased a new stake in shares of NextCure in the 4th quarter valued at approximately $185,000. Geode Capital Management LLC lifted its holdings in shares of NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares during the last quarter. Renaissance Technologies LLC increased its holdings in NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after purchasing an additional 5,300 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in NextCure in the fourth quarter valued at approximately $988,000. Institutional investors and hedge funds own 42.65% of the company’s stock.
About NextCure
NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.
The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.
Further Reading
- Five stocks we like better than NextCure
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
